Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $24.9 million.

  • Coherus Oncology's Accounts Payables rose 1370.3% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 1370.3%. This contributed to the annual value of $28.5 million for FY2024, which is 1920.27% down from last year.
  • As of Q3 2025, Coherus Oncology's Accounts Payables stood at $24.9 million, which was up 1370.3% from $37.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Accounts Payables high stood at $76.8 million for Q2 2024, and its period low was $9.9 million during Q3 2022.
  • For the 5-year period, Coherus Oncology's Accounts Payables averaged around $28.7 million, with its median value being $24.9 million (2025).
  • As far as peak fluctuations go, Coherus Oncology's Accounts Payables soared by 28120.93% in 2021, and later crashed by 7830.31% in 2022.
  • Coherus Oncology's Accounts Payables (Quarter) stood at $16.2 million in 2021, then dropped by 28.67% to $11.5 million in 2022, then skyrocketed by 205.56% to $35.2 million in 2023, then fell by 19.2% to $28.5 million in 2024, then decreased by 12.52% to $24.9 million in 2025.
  • Its last three reported values are $24.9 million in Q3 2025, $37.6 million for Q2 2025, and $40.9 million during Q1 2025.